Navigation Links
Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
Date:3/19/2008

NEW YORK, March 19 /PRNewswire/ -- More than 90% of drugs entering clinical development fail to get to market, due to the lack of effectiveness or adverse side effects not detected in animal tests. These false positives could be avoided with pre-clinical tests using stem cell technologies, potentially saving drug developers millions, according to Kalorama Information's new report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

The discovery and commercialization of a new drug costs in excess of $1 billion and requires more than 14 years. Early toxicity testing is a particular problem, since there are currently no good models for determining whether a drug will be toxic in humans. Some unsafe products advance through testing and approval, only to be pulled from the market later at a huge expense, as was the case with Vioxx and Bextra.

Though stem cell-based drug development technologies are in an early stage of development, and will most likely not become available before 2012 at the earliest, their prospects are promising.

"The excitement around stem cells has understandably been in the potential for therapy, but drug development is where they may have the most impact on healthcare," notes Bruce Carlson, publisher of Kalorama Information. "Stem cell technology could provide a virtually endless supply of liver or heart cells for testing, saving developers tens, if not hundreds of millions of dollars in direct testing fees, as well as indirect costs related to drug recalls."

Recognizing stem cells' potential, GlaxoSmithKline, AstraZeneca and Roche established a new venture in 2007, Stem Cells for Safer Medicines Ltd., to develop effective ways of using human ES cells to screen for potentially dangerous side effects of new drugs before they go into clinical trials.

Kalorama Information's report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development discusses critical issues and trends in this exciting new field. The information and forecasts presented through 2020 were gathered through secondary research and interviews conducted with industry executives. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Stem-Cells-Worldwide-1597988/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
2. New England Technology Foundation Announces Connecting for Childrens Charities 2008 Event
3. Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future
4. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
5. New Technology No Better at Spotting Anesthesia Awareness
6. Virtual reality and computer technology improve stroke rehabilitation
7. Advanced Technology in Dental Imaging Benefits Patients
8. Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyses Advanced Technology Solution
9. Vendormate Again Selected as Top 40 Georgia Innovative Technology Company
10. Breakthrough Seating Technology, ergoSEET(TM), Now Available in Indianapolis
11. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at ... and joint health in horses at the immunologic level. , The scientifically-developed Flexadin ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the ... Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than ... marketer in the last 25 years. , Now, due to changes in the broadcast ...
(Date:4/24/2017)... Virginia (PRWEB) , ... April 24, 2017 , ... ... announced that they are seeking public support to bring their novel lifesaving device ... appearance, wearable device packed with medical-grade sensors, specially designed to read a child’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology: